Logo Logo
Hilfe
Hilfe
Switch Language to English

Elander, N. O.; Aughton, K.; Ghaneh, P.; Neoptolemos, J. P.; Palmer, D. H.; Cox, T. F.; Campbell, F.; Costello, E.; Halloran, C. M.; Mackey, J. R.; Scarfe, A. G.; Valle, J. W.; McDonald, A. C.; Carter, R.; Tebbutt, N. C.; Goldstein, D.; Shannon, J.; Dervenis, C.; Glimelius, B.; Deakin, M.; Charnley, R. M.; Anthoney, A.; Lerch, M. M.; Mayerle, J.; Olah, A.; Buchler, M. W. und Greenhalf, W. (2018): Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. In: British Journal of Cancer, Bd. 118, Nr. 8: S. 1084-1088

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

BACKGROUND: Deoxycytidylate deaminase (DCTD) and ribonucleotide reductase subunit M1 (RRM1) are potential prognostic and predictive biomarkers for pyrimidine-based chemotherapy in pancreatic adenocarcinoma. METHODS: Immunohistochemical staining of DCTD and RRM1 was performed on tissue microarrays representing tumour samples from 303 patients in European Study Group for Pancreatic Cancer (ESPAC)-randomised adjuvant trials following pancreatic resection, 272 of whom had received gemcitabine or 5-fluorouracil with folinic acid in ESPAC-3(v2), and 31 patients from the combined ESPAC-3(v1) and ESPAC-1 post-operative pure observational groups. RESULTS: Neither log-rank testing on dichotomised strata or Cox proportional hazard regression showed any relationship of DCTD or RRM1 expression levels to survival overall or by treatment group. CONCLUSIONS: Expression of either DCTD or RRM1 was not prognostic or predictive in patients with pancreatic adenocarcinoma who had had post-operative chemotherapy with either gemcitabine or 5-fluorouracil with folinic acid.

Dokument bearbeiten Dokument bearbeiten